Wet AMD can cause irreversible vision loss, and patients face a high treatment burden, often leading to missed appointments. This #HealthyVisionMonth, we’re advancing our Phase 3 #WetAMD program and are proud to partner with Foundation Fighting Blindness in the fight against #RetinalDiseases.

✅ 400+ patients enrolled & randomized in 7 months 1️⃣ First pivotal trial in global Phase 3 program 📈 Topline data expected mid-2026 👉 Check out more on our latest milestone and what’s next for LUCIA here: investors.eyepointpharma.com/news-releases/…

#ICYMI We announced our pivotal Phase 3 LUGANO trial in wet AMD has been fully enrolled & randomized in seven months! This milestone couldn't have been accomplished without the support, dedication & hard work from the investigators and study coordinators involved in this trial.

Our $EYPT team is gearing up for next month and looking forward to sharing more on our innovative #RetinaPipeline at upcoming conferences.

We are proud to share that #EYPT has renewed our sponsorship for the American College of Eye Technicians (ACET), underscoring our commitment to this non-profit organization helping to educate, train and then place graduates at ophthalmology practices.

#TOMORROW $EYPT we will be attending the Jefferies Global Healthcare Conference in the big🍎. Looking forward to sharing more about our ongoing #ClinicalTrials and connecting with other leaders in the healthcare industry!

Please join us in welcoming our Summer 2025 intern class at $EYPT! We look forward to working with each of our new interns, providing them with first-hand experience and opportunities. #FormulateYourFuture

Our $EYPT team is gearing up for the Goldman Sachs 46th Annual Global Healthcare Conference, next week. Looking forward to connecting with the investor community at this event!

We are pleased to share two significant milestones in our global pivotal Ph 3 wet AMD program: 1️⃣First patient outside of the U.S. has been dosed in our Ph 3 LUCIA trial 2️⃣Received approval for our Ph 3 trial protocol in Europe, underscoring strategic & thoughtful trial design

Our company culture stems from our team at #EYPT. They are our greatest strength, and their determination and collaboration foster an environment of innovation.

“I always say it's very easy to identify problems. It's not so easy to come up with the solutions or even the right solution. And that's really what we try to do on a daily basis here.” - Jay S. Duker, M.D., $EYPT President and CEO. Hear more below on our innovation and

Our team is off to sunny California to present 3 posters on our DAVIO and VERONA clinical trials at this year’s ASRS Annual Meeting in Long Beach.

Over 800 patients have now been enrolled across LUGANO and LUCIA, representing one of the fastest enrolling pivotal phase 3 programs for wet AMD. 📈 Topline LUGANO data expected mid-2026 with LUCIA to closely follow. 👉 Check out more here:

#ICYMI – Our pivotal Phase 3 LUCIA trial for wet AMD has fully enrolled and randomized over 400 patients in 7️⃣months! This milestone was accomplished by the diligent, dedicated and hard-working team of investigators and study coordinators. From everyone at EyePoint, thank you!

#InvestorNews: #EYPT reports Q2 2025 financial results & highlights recent corporate developments. Learn more about our latest progress, including next steps for our two Phase 3 pivotal wet AMD clinical trials here: investors.eyepointpharma.com/news-releases/…

#EYPT will be participating in the H.C. Wainwright & Co. Ophthalmology Virtual Conference on August 13, highlighting momentum in our pivotal Phase 3 wet AMD program and our continued commitment to advancing retinal innovation.

Our annual summer employee outing brought the #EYPT team and their loved ones together at Kimball Farm for a day of fun and celebration. It was the perfect chance to connect, recharge, and recognize everything we’ve accomplished.

August is National Eye Exam Month — a time to spotlight the power of prevention. At EyePoint, we’re committed to advancing innovative treatments for serious retinal diseases like wet AMD. Routine eye exams aren’t just about updating your prescription; they’re often the first

Our core values come to life every day at EYPT, shaping how we innovate, collaborate and deliver on our promise to improve the lives of patients with serious retinal diseases.

With the most extensively studied TKI in retinal disease, robust safety data, and no TIE2 inhibition, we’re advancing a potential novel mechanism of action for wet AMD treatment — driven by science, guided by patient needs. Learn more about our progress: